Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
October 15, 2024 14:30 ET
|
Tevogen Bio Inc
Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions.Tens of thousands of women in the US each year are diagnosed with high-grade cervical...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024 16:10 ET
|
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines
March 28, 2024 08:05 ET
|
Unity Consortium
Unity Consortium marks Adolescent Immunization Action Week, April 1-5, 2024, encouraging parents and adolescents to get up to date on recommended vaccines
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024 07:00 ET
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Cervical Cancer Studies Outline Innovative Treatment Options For Patients In 2024
February 15, 2024 11:42 ET
|
Allsup
Belleville, Illinois, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Groundbreaking research studies of the latest cervical cancer treatments are illuminating new paths for patients and highlighting the...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
November 10, 2023 07:00 ET
|
Microbix Biosystems Inc.
Microbix secures a new European collaborator, Ulisse Biomed, in relation to HPV testing and cervical cancer screening.